Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on
response when metastatic breast cancer patients are treated with DNA damaging chemotherapy
agent, compared to historical controls
Secondary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on
tumor progression when metastatic breast cancer patients are treated with DNA damaging
chemotherapy agent, compared to historical controls